Answers are grounded in this paper and cite their sources.
Current anti-obesity therapies that suppress appetite often cause undesirable reductions in lean mass by indirectly depleting systemic energy store. In this study, we developed a novel anti-obesity drug, Vutiglabridin (VUTI), designed to selectively reduce fat mass while preserving lean mass. We evaluated its efficacy in high-fat diet–induced obese (DIO) mice and investigated its underlying mechanism in in vitro adipocyte models. VUTI dose-dependently and selectively decreased fat mass, resulting in normalization of body weight within 3 weeks while preserving lean mass. Pharmacokinetic and mechanistic analyses revealed that VUTI targets white adipose tissue (WAT), where it enhances lipid degradation through AMPK-mediated lipophagy in both mouse and human adipocytes. The lipid degradation-enhancing effect of VUTI was shown to be dependent on paraoxonase 2 (PON2). Multi-omics analyses, including proteomic and transcriptomic profiling of epididymal WAT in DIO-mice, further confirmed this mechanism. Collectively, these findings demonstrate that VUTI represents a promising therapeutic strategy for obesity by inducing fat-selective reduction via AMPK-mediated lipophagy. • PON2 activity is reduced and AMPK signaling is suppressed in adipose tissue of DIO mice. • Vutiglabridin preferentially distributes to adipose tissue and induces fat-selective weight loss. • Vutiglabridin enhances PON2 activity and promotes AMPK/lipophagy-mediated lipolysis in adipocytes. • Vutiglabridin represents a new therapeutic strategy that selectively reduces fat to improve obesity.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: